IBB250516C110000
- 16.90
- +0.70+4.32%
iShares Biotechnology ETF Newsroom
Vertex Pharmaceuticals Q1 2025 Earnings Preview
Notable Healthcare Headlines for the Week: Gilead, CVS Health, Sanofi in Focus
Earnings Week Ahead: AMD, PLTR, F, DIS, SHOP, DKNG, AMC, LCID, GOLD, RIVN, and More
Healthcare Sector Flexes Earnings Muscle, but Top-line Cracks Show
Gilead and Vertex Pharma Named Among Biotech's Tariff Safe Havens
Earnings Outlook For Vertex Pharmaceuticals
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $320
Amgen Analyst Ratings
Mettler-Toledo Outlines 2025 EPS Guidance Amid Ongoing Tariff Challenges
Peering Into Natera's Recent Short Interest
Amgen Unusual Options Activity For May 02
Sector Update: Health Care Stocks Rise Premarket Friday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Weigh Mix of Earnings, Rise in US Nonfarm Payrolls
4 Stocks to Watch on Friday: XOM, CVX, AMGN and TTWO
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325
Alnylam Pharmaceuticals Analyst Ratings
Earnings Call Summary | Amgen(AMGN.US) Q1 2025 Earnings Conference
Amgen Beats on Both Lines and Reaffirms Guidance; Stock Flat Post Market
Mettler-Toledo Non-GAAP EPS of $8.19 Beats by $0.31, Revenue of $883.74M Beats by $7.9M